Proposal for multiple new lesions as complement of hyperprogressive disease in NSCLC patients treated with PD-1/PD-L1 immunotherapy
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference23 articles.
1. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;New Engl. J. Med.,2016
2. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;New Engl. J. Med.,2015
3. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC;Herbst;New Engl. J. Med.,2020
4. Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer;Kim;Ann. Oncol.,2019
5. Clarification of definitions of hyperprogressive disease during immunotherapy for non-small cell lung cancer;Kas;JAMA Oncol.,2020
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Redefining Clinical Hyperprogression: The Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy;Clinical Lung Cancer;2024-06
2. Hyperprogressive disease under anti-PD-1 rechallenge after initial response to anti-PD-1 treatment for non-small cell lung cancer: a case report;Translational Lung Cancer Research;2024-03
3. Redefining Clinical Hyperprogression: the Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy;2024-01-05
4. Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer;Frontiers in Immunology;2023-05-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3